8-K: CONMED Reports Q4, Full-Year 2025 Results; Offers 2026 Outlook

CONMED Corporation announced its fourth quarter and full-year 2025 financial results, highlighting sales growth and providing its 2026 financial outlook.

Summary

• Fourth Quarter 2025 sales reached $373.2 million, an increase of 7.9% year-over-year as reported and 7.1% in constant currency.
• Domestic revenue for Q4 2025 increased 1.4% year-over-year, while international revenue grew 17.0% as reported and 15.4% in constant currency.
• Diluted net earnings per share (GAAP) for Q4 2025 were $0.54, a decrease from $1.08 in Q4 2024.
• Adjusted diluted net earnings per share for Q4 2025 were $1.43, an increase from $1.34 in Q4 2024.
• Full-Year 2025 sales totaled $1,374.7 million, up 5.2% year-over-year as reported and 5.1% in constant currency.
• Domestic revenue for Full-Year 2025 increased 3.5%, and international revenue increased 7.4% as reported and 7.1% in constant currency.
• Diluted net earnings per share (GAAP) for Full-Year 2025 were $1.51, a significant decrease from $4.25 in 2024.
• Adjusted diluted net earnings per share for Full-Year 2025 were $4.59, an increase from $4.17 in 2024.
• For Full-Year 2026, the company expects reported revenue between $1.345 billion and $1.375 billion, representing organic constant currency growth of approximately 4.5% to 6% (excluding gastroenterology products).
• Full-Year 2026 adjusted diluted net earnings per share are projected to be in the range of $4.30 to $4.45, including a currency tailwind of approximately $0.10.

Sentiment

Score: 4

Explanation: While sales growth and adjusted EPS increased, the significant decline in GAAP EPS for both the quarter and full year, coupled with a lower adjusted EPS outlook for 2026 compared to 2025, indicates underlying challenges and substantial non-recurring costs. The positive sales growth is overshadowed by profitability concerns on a GAAP basis.

Positives

• Strong sales growth in Q4 2025 (7.9% reported, 7.1% constant currency) and Full-Year 2025 (5.2% reported, 5.1% constant currency).
• Significant international revenue growth in Q4 2025 (17.0% reported) and Full-Year 2025 (7.4% reported).
• Increase in adjusted diluted net earnings per share for both Q4 2025 (to $1.43 from $1.34) and Full-Year 2025 (to $4.59 from $4.17).
• Growth across both Orthopedic Surgery (Q4: 13.2% reported; FY: 5.6% reported) and General Surgery (Q4: 4.3% reported; FY: 4.9% reported) segments.
• Positive 2026 revenue outlook projecting 4.5% to 6% organic constant currency growth.
• Gross profit margin improved in Q4 2025 to 58.5% from 57.3% in Q4 2024.

Negatives

• Significant decline in GAAP diluted net earnings per share for Q4 2025 (to $0.54 from $1.08) and Full-Year 2025 (to $1.51 from $4.25).
• Full-Year 2025 Capital Products sales decreased by 2.1% as reported.
• The 2026 adjusted diluted net earnings per share outlook ($4.30 to $4.45) is lower than the Full-Year 2025 adjusted EPS ($4.59).
• Numerous non-GAAP adjustments in 2025, including significant operational optimization costs ($25.376 million), product rationalization costs ($24.483 million), contingent consideration fair value adjustments ($22.951 million expense), executive transition costs ($12.165 million), and debt refinancing costs ($0.418 million), indicate substantial non-recurring expenses impacting GAAP profitability.

Risks

• General industry and economic conditions could cause actual results, performance, or trends to differ materially from forward-looking statements.
• Risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024.
• Risks and uncertainties detailed from time to time in reports filed by CONMED with the SEC.
• Factors that could cause actual results to differ materially from those in the forward-looking statements.

Future Outlook

CONMED expects full-year 2026 reported revenue between $1.345 billion and $1.375 billion, representing organic constant currency growth of approximately 4.5% to 6% when excluding sales of gastroenterology products from both years. The company anticipates full-year 2026 adjusted diluted net earnings per share in the range of $4.30 to $4.45, which includes an estimated currency tailwind of approximately $0.10.

Management Comments

• "Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives."
• "As we begin 2026 with a sharpened strategic focus, we remain disciplined in our operating approach and confident in the long-term potential of our key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair."

Industry Context

The medical technology sector continues to demonstrate demand for specialized surgical devices, particularly in areas like minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair, which CONMED has identified as core growth drivers. The company's strong international revenue growth, significantly outpacing domestic growth, suggests robust market penetration or higher demand in global markets for its products. The ongoing operational optimization and product rationalization initiatives reflect a broader industry trend towards enhancing efficiency and strategically managing product portfolios, especially in response to evolving regulatory environments such as the European Union's Medical Device Regulations (MDR).

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark CONMED's performance against industry standards.
• CONMED's focus on high-growth segments like minimally invasive surgery and orthopedic soft tissue repair aligns with key strategic areas for innovation and market expansion within the broader medical device industry.
• The significant decline in GAAP EPS, despite adjusted EPS growth, suggests that CONMED's profitability on a reported basis may be lagging some industry peers who have managed to absorb or avoid similar levels of one-time operational and transition costs.

Legal Proceedings

• Incurred costs for third-party services pertaining to potential issues with certain royalty payments to design surgeons in both 2025 and 2024.

Stakeholder Impact

• Shareholders are impacted by the significant decline in GAAP EPS, though adjusted EPS growth and sales growth offer a more positive view. The 2026 outlook provides future guidance.
• Customers may be affected by product rationalization, including the discontinuation of certain catalog numbers.
• Employees may be indirectly impacted by operational optimization and product rationalization initiatives, though no specific workforce reductions were announced in 2025 (unlike 2024 which had severance costs).

Next Steps

• Host a conference call on January 28, 2026, at 4:30 p.m. ET to discuss the fourth quarter and full-year 2025 results.
• Continue disciplined operating approach and focus on key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.

Key Dates

Recommendation

CONMED demonstrates solid sales growth, particularly in international markets, and an improvement in adjusted earnings per share. However, the substantial decline in GAAP EPS for both the quarter and full year, alongside a lower adjusted EPS outlook for 2026 compared to 2025, raises concerns about underlying profitability and the impact of numerous non-recurring charges. The company is actively engaged in operational optimization and product rationalization, which could yield long-term benefits but currently obscure a clear picture of sustainable financial performance. Investors should hold to monitor the effectiveness of these strategic initiatives and the company's ability to translate sales growth into consistent GAAP profitability.

Keywords

CONMED, CNMD, financial results, earnings, medical technology, surgical devices, orthopedics, general surgery, minimally invasive surgery, smoke evacuation, soft tissue repair, Q4 2025, full-year 2025, 2026 outlook, SEC filing